PTX

0.00%

3.9¢ prescient therapeutics limited

I must admit I am very interested in how Kras is progressing. It...

First 1597 Last

Share
Profile

Follow
dalts66

4,361 Posts.

2034

19/07/24

14:01

Post #: 74829435
Share

Originally posted by Shellbell: ↑

I read the article earlier which arrived amongst my emails and immediately thought "Dalts will find this interesting"! Lo and behold you had seen it too.

I wondered if Kras targeted therapies could possibly have applications beyond oncology. There has been a move away from immunotherapies for the treatment of cancer to the treatment of immune-based diseases lately. It's been stated that treating cancer with immunotherapy is proving very difficult and too challenging. And, there we go... Lumakras found successful in treating a rare non-oncological disease in humans. Whether PTX-100 could have potential beyond cancer is an unknown and different matter... and one thing at a time, I guess! LOL

Quite an astounding result with Lumakras. This according to the article:-

Meanwhile, Canaud’s lab was studying KRAS in mouse models and found that in KRAS-mutated mice, administering Lumakras reduced blood vessel abnormalities. Mutant mice dosed with Lumakras also lived longer than those who were not.

The first patient in the new study had “severe and growing” AVM on the right side of his face since birth, for which he had received 11 surgeries that had led him to become blind in his right eye. He was receiving opioids for pain from the growth and faced frequent bleeding, but had no other options left and was suggested palliative care.

Then, after he started Lumakras, he stopped taking opioids and antibiotics in just three months. His pain, bleeding and fatigue improved. At two years, the volume of the growth on the right side of his face decreased by nearly a third, and his appearance looked noticeably different.

“This patient was in the ICU permanently,” Canaud said. “And right now he has not been hospitalized since two and a half years [ago], which is amazing for him.”

Expand

I must admit I am very interested in how Kras is progressing. It wasnt that long ago that it was thought impossible to target. Now there are a couple of drugs out there that can do just that.

Its exciting to see where this leads. As we know PTX100 is, so far, the broadest spectrum of the Kras drugs.

Its great to see results as reported in this article.

PTX Price at posting: 4.2¢ Sentiment: Buy Disclosure: Held
16 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

There are more pages in this discussion • 17 more messages in this thread...

First 1597 Last

Add PTX (ASX) to my watchlist

(20min delay)
Last 3.9¢		Change 0.000(0.00%)		Mkt cap ! $31.40M

Open	High	Low	Value	Volume
3.9¢	4.0¢	3.8¢	$16.31K	421.6K

Buyers (Bids)

No.	Vol.	Price($)
1	47849	3.9¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	73928	2

View Market Depth

No.	Vol.	Price($)
1	47849	0.039
5	707297	0.038
8	387500	0.037
5	708916	0.036
3	253590	0.035

Price($)	Vol.	No.
0.040	73928	2
0.041	200000	2
0.042	499154	4
0.043	449950	2
0.045	217151	3

Last trade - 16.10pm 27/09/2024 (20 minute delay)

PTX (ASX) Chart

I must admit I am very interested in how Kras is progressing. It...

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I must admit I am very interested in how Kras is progressing. It...

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News